Brokers Offer Predictions for Merck & Co., Inc.’s Q4 2025 Earnings (NYSE:MRK)

Merck & Co., Inc. (NYSE:MRK) – Analysts at Leerink Partnrs boosted their Q4 2025 earnings per share estimates for shares of Merck & Co., Inc. in a research note issued on Saturday, April 20th. Leerink Partnrs analyst D. Graybosch now anticipates that the company will post earnings of $2.39 per share for the quarter, up from their prior estimate of $2.37. The consensus estimate for Merck & Co., Inc.’s current full-year earnings is $8.59 per share.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Thursday, February 1st. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.12. Merck & Co., Inc. had a return on equity of 9.33% and a net margin of 0.61%. The company had revenue of $14.63 billion during the quarter, compared to analysts’ expectations of $14.49 billion. During the same quarter in the previous year, the firm earned $1.62 EPS. Merck & Co., Inc.’s revenue was up 5.8% on a year-over-year basis.

Other equities analysts have also recently issued research reports about the company. UBS Group upped their target price on Merck & Co., Inc. from $135.00 to $148.00 and gave the stock a “buy” rating in a report on Friday, February 2nd. Berenberg Bank upped their target price on Merck & Co., Inc. from $140.00 to $143.00 and gave the stock a “buy” rating in a report on Monday, April 8th. Wells Fargo & Company upped their target price on Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 27th. TD Cowen raised Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $125.00 to $135.00 in a report on Thursday, January 4th. Finally, Societe Generale cut Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 target price for the company. in a report on Monday, March 11th. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and a consensus target price of $131.25.

Merck & Co., Inc. Price Performance

Merck & Co., Inc. stock opened at $126.94 on Tuesday. Merck & Co., Inc. has a 52 week low of $99.14 and a 52 week high of $133.10. The stock has a fifty day moving average of $126.24 and a 200-day moving average of $115.51. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.00 and a current ratio of 1.25. The stock has a market capitalization of $321.54 billion, a P/E ratio of 906.71, a price-to-earnings-growth ratio of 1.63 and a beta of 0.38.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Stonegate Investment Group LLC boosted its holdings in Merck & Co., Inc. by 0.3% in the first quarter. Stonegate Investment Group LLC now owns 24,915 shares of the company’s stock worth $3,288,000 after acquiring an additional 79 shares in the last quarter. NTV Asset Management LLC boosted its holdings in Merck & Co., Inc. by 0.3% in the fourth quarter. NTV Asset Management LLC now owns 26,534 shares of the company’s stock worth $2,893,000 after acquiring an additional 80 shares in the last quarter. Hendershot Investments Inc. boosted its holdings in Merck & Co., Inc. by 0.5% in the first quarter. Hendershot Investments Inc. now owns 15,756 shares of the company’s stock worth $2,079,000 after acquiring an additional 81 shares in the last quarter. SRS Capital Advisors Inc. boosted its holdings in Merck & Co., Inc. by 1.6% in the fourth quarter. SRS Capital Advisors Inc. now owns 5,037 shares of the company’s stock worth $549,000 after acquiring an additional 81 shares in the last quarter. Finally, Endowment Wealth Management Inc. boosted its holdings in Merck & Co., Inc. by 3.2% in the fourth quarter. Endowment Wealth Management Inc. now owns 2,637 shares of the company’s stock worth $288,000 after acquiring an additional 81 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Insider Activity at Merck & Co., Inc.

In related news, EVP Steven Mizell sold 50,694 shares of the company’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the sale, the executive vice president now owns 23,619 shares in the company, valued at approximately $2,991,346.35. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, EVP Steven Mizell sold 50,694 shares of the company’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the sale, the executive vice president now owns 23,619 shares in the company, valued at approximately $2,991,346.35. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Joseph Romanelli sold 1,000 shares of the company’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $124.89, for a total value of $124,890.00. Following the sale, the insider now owns 19,569 shares in the company, valued at approximately $2,443,972.41. The disclosure for this sale can be found here. 0.09% of the stock is owned by corporate insiders.

Merck & Co., Inc. Company Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.